α-Santalol/Sandalwood oil / Casp3 Cancer Research Results

SAO, α-Santalol/Sandalwood oil: Click to Expand ⟱
Features:

α-Santalol / Sandalwood oil — α-Santalol is a lipophilic sesquiterpene alcohol and major bioactive constituent of East Indian sandalwood oil from Santalum album. It is best classified as a natural-product small molecule / essential-oil sesquiterpenoid, with sandalwood oil functioning as a botanical mixture source rather than a single-compound drug. Standard abbreviations include α-SAN, alpha-santalol, and SAO or EISO for sandalwood album / East Indian sandalwood oil. The oncology evidence is primarily preclinical, strongest for skin, prostate, breast, and oral cancer models, with no established oncology indication.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptosis through caspase activation, PARP cleavage, mitochondrial involvement, and increased apoptotic signaling.
  2. Cell-cycle blockade, especially G2/M arrest, with reported tubulin interaction and mitotic disruption in oral cancer models.
  3. Suppression of AKT–survivin / IAP survival signaling, including reduced p-AKT, survivin, XIAP, PCNA, cyclin D, and CDC2 in prostate cancer models.
  4. Anti-migration and anti-invasive signaling through Wnt/β-catenin inhibition in breast cancer models.
  5. Anti-angiogenic signaling through VEGFR2–AKT/mTOR/p70S6K pathway suppression in prostate tumor models.
  6. Autophagy modulation, including AKT–mTOR-linked autophagy in prostate cancer and autophagy/cell death effects for whole sandalwood oil in proliferating keratinocytes.
  7. Skin chemopreventive modulation of UVB/chemical carcinogenesis pathways, including p53/caspase-associated apoptosis and inflammatory stress-response modulation.

Bioavailability / PK relevance: α-Santalol is a small, highly lipophilic sesquiterpene alcohol, so topical and transdermal exposure is plausible, but formal human systemic PK data are limited. Oral/transdermal use should be treated as formulation- and dose-dependent, and essential-oil exposure is not equivalent to purified α-santalol exposure.

In-vitro vs systemic exposure relevance: Most anticancer cell-culture studies use micromolar α-santalol concentrations, commonly around 20–75 μM depending on model and endpoint. These levels should be considered potentially above reliably documented human systemic exposure from sandalwood oil use, so in-vitro anticancer potency should not be interpreted as clinically achievable without dedicated PK/formulation data.

Clinical evidence status: Preclinical for cancer prevention/therapy. Small human and dermatology-oriented evidence exists for sandalwood album oil in non-oncology skin conditions, and one clinical-trial context appears related to oral mucositis/supportive care rather than anticancer efficacy. No approved oncology indication and no high-quality human RCT evidence for cancer treatment were identified.

α-Santalol and Sandalwood Oil Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Caspase apoptosis ↑ caspase-3, ↑ caspase-8, ↑ caspase-9, ↑ PARP cleavage, ↓ viability ↔ to modest toxicity at comparable experimental windows (model-dependent) R/G Pro-apoptotic anticancer effect Core mechanism across prostate, breast, and skin cancer models; includes intrinsic and extrinsic apoptotic signaling.
2 Mitochondria / MPTP ↑ mitochondrial apoptotic signaling, ↓ mitochondrial membrane integrity (model-dependent) ↔ uncertain R/G Amplifies apoptosis Mitochondrial involvement is supported mainly through caspase-9 and apoptotic readouts; direct MPTP evidence is not as strong as apoptosis evidence.
3 Cell cycle and tubulin ↑ G2/M arrest, ↓ tubulin polymerization, ↑ mitotic arrest ↔ uncertain G Anti-proliferative cytostasis and cytotoxicity Strong mechanistic relevance for oral cancer and skin/breast cancer models; tubulin interaction supports antimitotic classification.
4 AKT / survivin / IAP ↓ p-AKT, ↓ survivin, ↓ XIAP, ↓ PCNA, ↓ cyclin D, ↓ CDC2 ↔ uncertain G Reduces survival signaling and proliferation Important prostate-cancer axis; PI3K/AKT inhibition can enhance α-santalol-induced apoptosis.
5 Wnt / β-catenin migration ↓ β-catenin-linked migration and motility ↔ uncertain G Anti-migration effect Best supported in cultured breast cancer cells; therapeutic relevance remains preclinical.
6 VEGFR2 angiogenesis ↓ VEGFR2 signaling, ↓ AKT/mTOR/p70S6K, ↓ tumor angiogenesis ↔ uncertain G Anti-angiogenic effect Relevant to prostate tumor xenograft-type evidence; not yet clinically validated.
7 Autophagy / AKT-mTOR ↑ autophagy (context-dependent), ↓ AKT-mTOR signaling ↑ autophagy/cell death in proliferating keratinocytes with whole oil (context-dependent) G Context-dependent stress adaptation or cell death Autophagy may be protective in some prostate cancer contexts; combination strategies would need caution.
8 ROS / oxidative stress ↔ limited direct cancer-specific evidence for α-santalol as a primary ROS driver ↔ antioxidant effects reported in non-cancer models R/G Secondary or context-dependent redox modulation ROS is not a core anticancer mechanism unless a specific model/source directly shows ROS-dependent killing.
9 NRF2 ↔ insufficient direct α-santalol cancer evidence ↔ uncertain G Not a primary assigned mechanism
10 Glycolysis / HIF-1α ↔ insufficient direct evidence ↔ insufficient direct evidence G No clear primary modulation
11 Radiosensitization or chemosensitization ↔ limited direct evidence; possible apoptosis-combination rationale only ↔ uncertain G Unproven adjunct effect
12 Clinical Translation Constraint In-vitro potency may require exposure above documented human systemic levels Topical irritation or sensitization possible; systemic safety data limited G Limits clinical interpretation Major constraints are formulation, bioavailability, mixture variability, topical safety, and lack of oncology trials.

P: 0–30 min R: 30 min–3 hr G: >3 hr
Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
6442- SAO,    Medicinal properties of alpha-santalol, a naturally occurring constituent of sandalwood oil: review
- Review, RCC, NA
AntiTum↑, Apoptosis↑, TumCCA↑, *Inflam↓, selectivity↑, tumCV↓, Casp8↓, Casp9↓, Casp6↓, Casp3↓, cl‑PARP↑, angioG↓, VEGFR2↓, Akt↑, mTOR↓, TumCG↓, *GSTs↑, *antiOx↑, *ROS↓,
6443- SAO,    α-Santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation
- in-vitro, Pca, PC3
tumCV↓, Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, TumCG↓,
6445- SAO,    Antineoplastic Effects of α-Santalol on Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancer Cells through Cell Cycle Arrest at G2/M Phase and Induction of Apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10 - in-vitro, BC, MCF-10AT
tumCV↓, TumCP↓, selectivity↑, TumCCA↑, DNAdam↑, Casp↑, cl‑PARP↑, Casp3↑, Casp6↑, Casp7↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Akt↑, 1,   Apoptosis↑, 2,   Casp↑, 1,   Casp3↓, 1,   Casp3↑, 2,   Casp6↓, 1,   Casp6↑, 1,   Casp7↑, 1,   Casp8↓, 1,   Casp9↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 3,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   cl‑PARP↑, 3,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 1,   TumCG↓, 2,  

Migration ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGFR2↓, 1,  

Drug Metabolism & Resistance ⓘ

selectivity↑, 2,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 21

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSTs↑, 1,   ROS↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  
Total Targets: 4

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
3 α-Santalol/Sandalwood oil
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:407  Target#:42  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page